M. Ňachajová, J. Višňovský, T. Bielik, E. Kúdela, A. Gondová, J. Danko
SUMMARY
Uterine fibroids are the most common tumours of the female genital tract. The effect
of myomas on the quality of life and the overall cost of treatment are significant issues
worldwide. Primary prevention and treatment of early myoma disease are worthy
goals that might have a significant impact on health care systems. Several treatments
and prophylactic methods can be used in this endeavor. This paper presents current
data about lesser-known substances which may have a beneficial effect on the treatment
or prophylaxis of UFs and can be administered orally, serving as an alternative
(or complementary) to surgery or selective progesterone receptor modulators
(SPRMs). Early prevention and treatment of fibroids in women from high-risk
groups should be our priority. Innovative forms of fibroid management are under
intensive investigation. The next step in such projects should be appropriately constructed
randomised control trials, carried out by successive phases.